Quantcast
Last updated on April 19, 2014 at 17:21 EDT

Latest PEGylation Stories

2012-08-02 10:27:25

SAN FRANCISCO, Calif., Aug. 2, 2012 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the second quarter ended June 30, 2012 on Thursday, August 9, 2012, after the close of U.S.-based financial markets. Howard Robin, president and chief executive officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time (ET)/2:00 p.m. Pacific Time (PT). The press release and a live audio-only Webcast of the conference call can be...

2012-07-23 10:25:11

EAST BRUNSWICK, N.J., July 23, 2012 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) today announced that the Delaware Court of Chancery has issued a bench ruling granting both of Savient's motions in the lawsuit brought against the Company by Tang Capital Partners, LP and certain other holders of Savient's convertible notes. The Court of Chancery decided that the plaintiff noteholders do not have standing to bring an action to appoint a receiver for Savient and that an event of...

2012-07-17 10:24:48

EAST BRUNSWICK, N.J., July 17, 2012 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) announced today that the Company's second quarter 2012 financial results will be released prior to the market open on Wednesday, August 8, 2012. Savient's executive management will host a conference call beginning at 9:00 a.m. Eastern Time on August 8, 2012 to discuss these results and to answer questions. To participate by telephone, please dial 866-393-1565 (Domestic) or 253-237-1151...

2012-05-30 10:25:21

SAN FRANCISCO, May 30, 2012 /PRNewswire/ -- Nektar Therapeutics' (Nasdaq: NKTR) President and Chief Executive Officer, Howard W. Robin, is scheduled to present at the Jefferies 2012 Global Healthcare Conference at The Grand Hyatt New York on Tuesday, June 5, 2012 at 11:30 a.m. Eastern Time. The presentation will be accessible via a Webcast through a link posted on the Investor Relations, Events Calendar section of the Nektar website http://www.nektar.com. This webcast will be available for...

2012-05-29 22:20:39

SEATTLE, May 30, 2012 /PRNewswire/ -- Aequus BioPharma, Inc. ("Aequus"), a majority owned subsidiary of Cell Therapeutics, Inc. ("CTI") (NASDAQ and MTA: CTIC), announced today that its GlycoPolymer technology proof of concept studies, featuring recent data with their AQB-101 drug candidate, was selected for an oral presentation at the 9th International Symposium for Polymer Therapeutics meeting. The meeting will be held on May 28-30, 2012, at the Centro de Investigacion Principe Felipe in...

2012-05-01 21:32:14

There's a high rate of depression among patients with hepatitis C, but a standard treatment for the disease includes a drug, interferon, that can cause depression. In a review article, researchers tackle the complexities of diagnosing and managing depression before and after initiating treatment with interferon. Dr. Murali S. Rao of Loyola University Medical Center is a co-author of the study, published in the International Journal of Interferon, Cytokine and Mediator Research....

2012-04-26 10:25:39

( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) DUBLIN and LANGHORNE, Pa., April 26, 2012 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and EUSA Pharma Inc. today announced that the companies have signed a definitive agreement under which Jazz Pharmaceuticals has agreed to acquire EUSA Pharma, a privately-held, specialty pharmaceutical company with headquarters in the United States and United Kingdom, for $650 million in cash(1) and a potential $50 million milestone payable in cash based upon its...

2012-04-25 02:32:51

SAN FRANCISCO, April 25, 2012 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the first quarter ended March 31, 2012 on Wednesday, May 2, 2012, after the close of U.S.-based financial markets. Howard Robin, president and chief executive officer, will host a conference call to provide a general business update and review the first quarter results beginning at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time. The press release and a live audio-only...

2012-04-20 10:22:15

EAST BRUNSWICK, N.J., April 20, 2012 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) announced today that the Company's first quarter financial results will be released prior to the open of the market on Wednesday, May 9, 2012. Savient executive management will host a conference call beginning at 9:00 a.m. Eastern Time on May 9, 2012, to discuss these results and to answer questions. To participate by telephone, please dial 866-393-1565 (Domestic) or 253-237-1151...

2012-04-04 06:24:03

HUDDINGE, Sweden, April 4, 2012 /PRNewswire/ -- - Including an Oral Presentation of final analysis of the TMC435 phase IIb ASPIRE (C206) study that have been selected to be highlighted during the official EASL Press Office activities Medivir AB (OMX: MVIR), a research-based specialty pharmaceutical company focused on infectious diseases, today announces that four abstracts related to its once daily (QD), oral investigational hepatitis C drug TMC435, development in...